Absci CORP 8-K filings

Absci Corporation has priced an underwritten public offering of 13,495,277 shares of common stock at $7.41 per share to raise approximately $100 million.

Absci Corporation announced favorable interim Phase 1 safety and pharmacokinetic results for ABS-201, its AI-designed antibody targeting hair loss and endometriosis.

Absci Corporation stockholders re-elected Class II directors and ratified the appointment of Ernst & Young LLP as auditors.

Absci Corporation announced its first quarter 2026 financial and operating results, highlighting progress in its ABS-201 clinical trials for androgenetic alopecia and endometriosis, and the addition of ABS-202 to its pipeline.

Absci Corporation announced its fourth quarter and full year 2025 financial results, highlighted by clinical progress for ABS-201 in hair loss and endometriosis, and advancements in its AI-driven drug discovery platform.

Absci Corporation announced the appointment of Ransi Somaratne, M.D., as Chief Medical Officer, the retirement of Chief Innovation Officer Andreas Busch, and updated director and officer indemnification agreements.

Absci Corporation presented a business update at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its generative AI drug creation platform and clinical pipeline progress.

Absci Corporation reported Q3 2025 financial results, accelerated its ABS-201 program for androgenetic alopecia and endometriosis, and extended its cash runway into the first half of 2028.

Absci Corporation announced the final distribution of milestone consideration related to its 2021 merger with Totient, Inc., resulting in Absci receiving approximately $8.7 million.

Absci reports Q2 2025 financial results, highlights expanded Almirall collaboration, pipeline progress, and extended cash runway into H1 2028.

Absci Corporation announced its second quarter 2025 financial results, reporting an increased net loss and decreased revenue, but significantly strengthened its balance sheet with a $64 million capital raise, extending its cash runway into the first half of 2028.

Absci Corporation announced the pricing of a public offering of 16.67 million common shares at $3.00 per share, aiming to raise approximately $46.7 million in net proceeds to advance its AI-driven drug creation platform and internal asset programs.

Absci Corporation has appointed Mary Szela, CEO of Trisalus Life Sciences, to its Board of Directors, effective July 7, 2025, expanding the board to seven members.

Absci Corporation announced that its stockholders approved the re-election of Frans van Houten and Karen McGinnis as Class I directors and ratified Ernst & Young LLP as its independent registered public accounting firm for the 2025 fiscal year at the Annual Meeting held on June 11, 2025.

Absci Corporation announces the start of its first-in-human study for ABS-101 and reports its financial results for the first quarter of 2025, highlighting progress in its pipeline and partnerships.

Amrit Nagpal resigned from Absci Corporation's Board of Directors and all committees, effective April 25, 2025.

Absci Corporation reported its Q4 and full-year 2024 financial results, showcasing advancements in its AI-driven drug creation platform and strategic collaborations.

Absci Corporation announces a business update presentation at the J.P. Morgan Healthcare Conference, showcasing its generative AI drug creation platform and advancements in its therapeutic pipeline.

Absci Corporation announced its third quarter 2024 financial results, showcasing progress in AI-driven drug discovery and key partnerships.

Absci has successfully completed the first milestone in its AI-driven drug discovery collaboration with AstraZeneca, delivering AI-designed antibody sequences for an oncology target.

Absci Corporation announced positive results from non-human primate studies for its lead drug candidate, ABS-101, and a new collaboration with Memorial Sloan Kettering Cancer Center.

Absci Corporation held its annual meeting on June 12, 2024, where stockholders elected three Class III directors and ratified the appointment of Ernst & Young LLP as the company's independent auditor.

Absci Corporation announced its first quarter 2024 financial results, highlighting progress in its internal pipeline and drug creation partnerships.

Absci announced its fourth quarter and full year 2023 financial results, highlighted by a new collaboration with AstraZeneca, progress in its internal pipeline, and a successful $86 million capital raise.

Absci Corporation has launched a public offering of 16.7 million shares of common stock, aiming to raise approximately $75.2 million to support its drug development programs and AI platform.

Absci Corporation released preliminary unaudited financial results for 2023 and detailed a strategic shift in its business model towards a diversified portfolio of partnered and internal drug development programs.